[go: up one dir, main page]

PE20240242A1 - Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico - Google Patents

Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico

Info

Publication number
PE20240242A1
PE20240242A1 PE2023003221A PE2023003221A PE20240242A1 PE 20240242 A1 PE20240242 A1 PE 20240242A1 PE 2023003221 A PE2023003221 A PE 2023003221A PE 2023003221 A PE2023003221 A PE 2023003221A PE 20240242 A1 PE20240242 A1 PE 20240242A1
Authority
PE
Peru
Prior art keywords
indol
pyrazole
cyano
isopropyl
pharmaceutical composition
Prior art date
Application number
PE2023003221A
Other languages
English (en)
Inventor
Jieun Lee
Heemin Gwak
Seong Hye Shin
Ji Young Min
Min Hee Kim
Junyu Kim
Jung Youn Seo
June Sik Mune
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of PE20240242A1 publication Critical patent/PE20240242A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilo o una sal farmaceuticamente aceptable del mismo, para ser administrada por via oral a un sujeto en una dosificacion de 50 a 200 mg/dia, donde el sujeto tiene una tasa de filtracion glomerular estimada (eGFR) de menos de 90 mL/min/1,73 m2. Dicha composicion es util para tratar o prevenir una enfermedad relacionada con la hiperuricemia, tal como es gota, exacerbacion de gota recurrente, artritis gotosa, hipertension, enfermedad cardiovascular, cardiopatia coronaria, entre otras.
PE2023003221A 2021-06-15 2022-06-15 Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico PE20240242A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20210077709 2021-06-15
PCT/KR2022/008444 WO2022265378A1 (ko) 2021-06-15 2022-06-15 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 약학적 조성물

Publications (1)

Publication Number Publication Date
PE20240242A1 true PE20240242A1 (es) 2024-02-16

Family

ID=84525806

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2023003221A PE20240242A1 (es) 2021-06-15 2022-06-15 Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico
PE2023003210A PE20240241A1 (es) 2021-06-15 2022-06-15 Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilo

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2023003210A PE20240241A1 (es) 2021-06-15 2022-06-15 Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilo

Country Status (17)

Country Link
US (2) US20240293369A1 (es)
EP (2) EP4344701A4 (es)
JP (2) JP7668386B2 (es)
KR (2) KR20220168173A (es)
CN (2) CN117425477A (es)
AR (1) AR126153A1 (es)
AU (2) AU2022294728A1 (es)
BR (2) BR112023026415A2 (es)
CA (2) CA3221017A1 (es)
CL (2) CL2023003514A1 (es)
CO (2) CO2023016596A2 (es)
MX (2) MX2023014357A (es)
PE (2) PE20240242A1 (es)
PH (1) PH12023553231A1 (es)
TW (1) TWI888729B (es)
WO (2) WO2022265382A1 (es)
ZA (2) ZA202311241B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR126164A1 (es) * 2021-06-17 2023-09-27 Lg Chemical Ltd Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2133332T1 (sl) * 2007-04-11 2014-02-28 Kissei Pharmaceutical Co., Ltd. (aza)indolinski derivat in njegova uporaba v medicinske namene
TWI423962B (zh) * 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
TWI548630B (zh) 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
CN105579037A (zh) * 2013-05-31 2016-05-11 武田制药美国有限公司 用黄嘌呤氧化酶抑制剂治疗的方法和含黄嘌呤氧化酶抑制剂的组合物
JP2015160847A (ja) * 2014-02-28 2015-09-07 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 小分子のキサンチンオキシダーゼ阻害剤および使用方法
CN106008488B (zh) * 2016-05-20 2018-10-30 广东东阳光药业有限公司 氰基吲哚类衍生物及其制备方法和用途
BR112021006002A2 (pt) 2018-10-01 2021-06-29 Astrazeneca Ab composições para a redução de ácido úrico sérico
KR20220077091A (ko) 2020-12-01 2022-06-08 주식회사 엘지화학 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 안정한 경구용 제제

Also Published As

Publication number Publication date
BR112023026432A2 (pt) 2024-03-05
CL2023003513A1 (es) 2024-06-07
MX2023014359A (es) 2023-12-15
ZA202311241B (en) 2025-03-26
ZA202311237B (en) 2025-02-26
EP4344701A1 (en) 2024-04-03
WO2022265382A1 (ko) 2022-12-22
TW202308611A (zh) 2023-03-01
EP4360631A4 (en) 2025-05-21
AU2022294728A1 (en) 2024-01-04
CA3221533A1 (en) 2022-12-22
JP7668386B2 (ja) 2025-04-24
PE20240241A1 (es) 2024-02-16
MX2023014357A (es) 2023-12-15
CO2023016621A2 (es) 2023-12-11
CA3221017A1 (en) 2022-12-22
PH12023553231A1 (en) 2024-04-29
KR20220168172A (ko) 2022-12-22
CN117425477A (zh) 2024-01-19
CO2023016596A2 (es) 2023-12-11
US20240285583A1 (en) 2024-08-29
KR20220168173A (ko) 2022-12-22
JP2024520138A (ja) 2024-05-21
EP4360631A1 (en) 2024-05-01
CL2023003514A1 (es) 2024-05-03
EP4344701A4 (en) 2024-10-23
WO2022265378A1 (ko) 2022-12-22
CN117412746A (zh) 2024-01-16
JP2024520150A (ja) 2024-05-21
BR112023026415A2 (pt) 2024-03-05
AR126153A1 (es) 2023-09-13
TWI888729B (zh) 2025-07-01
AU2022292402A1 (en) 2023-12-14
TW202304428A (zh) 2023-02-01
US20240293369A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
CN103751194B (zh) 用于治疗病症的方法和组合物
MX2020014000A (es) Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas.
FI4014976T3 (fi) Aprositentaani käytettäväksi kohonneen verenpaineen ja siihen liittyvien sairauksien hoidossa yhdistelmänä valsartaanin kanssa
DOP2006000170A (es) Nuevos derivados de espirocromanona
RU2010118022A (ru) Фармацевтическая композиция валсартана
US20210155593A1 (en) Hdac inhibitors for the treatment of diabetic peripheral neuropathy
JP2010530901A5 (es)
PE20121407A1 (es) Composicion farmaceutica que comprende bis-(monoetanolamina) de acido 3'-[(2z)-[1-(3, 4-dimetilfenil)-1, 5-dihidro-3-metil-5-oxo-4h-pirazol-4-ilideno] hidrazino]-2'-hidroxi-[1, 1'-bifenil]-3-carboxilico
EP3915566A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY BOWEL DISEASE, CONTAINING TAURODEOXYCHOLIC ACID OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS THE ACTIVE INGREDIENT
US20160158231A1 (en) Pyrimidine hydroxy amide compounds for treating peripheral neuropathy
RU2010116526A (ru) Фармацевтическая комбинация алискирена и валсартана
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
PE20240242A1 (es) Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico
JP2024095711A (ja) 可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール
EA201992801A1 (ru) Способ получения соединения гетероциклического производного, композиции, содержащей указанное соединение, и гидрата указанного соединения
MX2025005223A (es) Agonistas del estimulador de genes de interferon (sting)
ECSP23017158A (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
WO2020236690A9 (en) Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
JP2006514051A (ja) 慢性心不全の治療
MX2025011536A (es) Forma polimorfica del clorhidrato de pitolisant
PE20210415A1 (es) Forma de dosificacion farmaceutica administrable por via oral con liberacion modificada
PE20240222A1 (es) Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion
CN108601784A (zh) 药物
RU2011134414A (ru) Комбинация фульвовой кислоты для лечения различных состояний и болезней
DK2091520T3 (da) Oral doseringsform omfattende trisubstituerede glycerol-forbindelser